Production of the soluble form of the Rabies virus glycoprotein ectodomain as a subunit vaccine candidate

G.A. Bayandy, Nuraiym Baltakhozha, K. Yerkinova, K. Nurpeis, G. Sailauova, Izat Smekenov, Amangeldy K. Bissenbaev

2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.26577/ijbch20251821
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Rabies remains a serious global public health concern. The envelope glycoprotein of the rabies virus (RABV-G) is the principal viral antigen and harbors critical neutralizing epitopes, making it a promising target for subunit vaccine development and diagnostic applications. Nevertheless, the efficient production of recombinant RABV-G with preserved antigenic and immunogenic properties remains technically demanding. In this work, we developed an optimized strategy for the expression and purification of recombinant RABV-G and assessed its antigenicity and immunogenicity. The rabies virus glycoprotein ectodomain (rRABV-GE) was successfully expressed in Escherichia coli Rosetta2(DE3)pLysS and purified in a biologically relevant form. The rRABV-GE gene was codon-optimized and cloned into the pET-28c(+) expression vector, resulting in recombinant protein expression largely in an insoluble state. Consequently, the protein was subjected to refolding and purification procedures. To improve protein solubility, hydrophobic loop regions were substituted with flexible linker sequences. Protein purification was performed under denaturing conditions using urea, followed by affinity chromatography. The identity and antigenicity of the purified protein were confirmed by Western blot analysis and indirect enzyme-linked immunosorbent assay (ELISA). ELISA testing was performed using rabbit sera collected from animals immunized with the commercial Purified Vero Cell Rabies Vaccine (RHABDOVAC-1). Collectively, these findings indicate that the optimized bacterial expression platform enables the production of biologically relevant rRABV-GE and provides a cost-effective approach for the development of rabies subunit vaccines and diagnostic reagents. In summary, the recombinant rRABV-G protein produced in this study appears to be a suitable diagnostic antigen for ELISA-based and other rabies virus immunodiagnostic uses. Keywords: Rabies virus, glycoprotein ectodomain, antibody, ELISA, Rosetta2(DE3)pLysS, vaccine.